pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
survodutide · news · pharmadog
← back to survodutide
News mentioning survodutide
13
stories
8d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
endpoints
13d
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
fiercebiotech
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 8, 26
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
Oct 1, 26
3 takeaways from a European obesity scientific meeting
biopharma dive
Oct 1, 26
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
Oct 1, 26
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
Aug 13, 26
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
Jun 7, 26
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
endpoints
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive